There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
AstraZeneca bags three of the month’s four oncology approvals.
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Firce-1 is scrapped after showing dismal response rates and patient deaths.
On a wing and a prayer Leap heads for phase 3.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
But the new focus on a predictive biomarker could cut the market in half.
